Montalban X, et al. Evaluation of No Evidence of Progression or Active Disease (NEPAD) in Patients With Primary Progressive Multiple Sclerosis in the ORATORIO Trial. PR2086. EAN 2017.
Modificeerbare overlappende risicofactoren voor beroerte, dementie en depressie
jul 2025 | Dementie, Neuro-vasculair